Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 212

1.

Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID.

Amiot A, Setakhr V, Seksik P, Allez M, Treton X, De Vos M, Laharie D, Colombel JF, Abitbol V, Reimund JM, Moreau J, Veyrac M, Flourié B, Cosnes J, Lemann M, Bouhnik Y.

Am J Gastroenterol. 2014 Sep;109(9):1443-9. doi: 10.1038/ajg.2014.183. Epub 2014 Aug 5.

PMID:
25091063
2.

Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data.

Chen GB, Lee SH, Brion MJ, Montgomery GW, Wray NR, Radford-Smith GL, Visscher PM; International IBD Genetics Consortium.

Hum Mol Genet. 2014 Sep 1;23(17):4710-20. doi: 10.1093/hmg/ddu174. Epub 2014 Apr 11.

3.

Biologic targeted therapies in pediatric rheumatology.

Guillaume-Czitrom S; Club Rhumatismes et Inflammations.

Joint Bone Spine. 2014 Feb;81 Suppl 1:2-48. doi: 10.1016/S1297-319X(14)70020-X. No abstract available.

PMID:
24661916
4.

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group.

Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25.

PMID:
24162591
5.

Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis.

Beaudoin M, Goyette P, Boucher G, Lo KS, Rivas MA, Stevens C, Alikashani A, Ladouceur M, Ellinghaus D, Törkvist L, Goel G, Lagacé C, Annese V, Bitton A, Begun J, Brant SR, Bresso F, Cho JH, Duerr RH, Halfvarson J, McGovern DP, Radford-Smith G, Schreiber S, Schumm PL, Sharma Y, Silverberg MS, Weersma RK; Quebec IBD Genetics Consortium; NIDDK IBD Genetics Consortium; International IBD Genetics Consortium, D'Amato M, Vermeire S, Franke A, Lettre G, Xavier RJ, Daly MJ, Rioux JD.

PLoS Genet. 2013;9(9):e1003723. doi: 10.1371/journal.pgen.1003723. Epub 2013 Sep 12.

6.

Analysis of single nucleotide polymorphisms in the region of CLDN2-MORC4 in relation to inflammatory bowel disease.

Söderman J, Norén E, Christiansson M, Bragde H, Thiébaut R, Hugot JP, Tysk C, O'Morain CA, Gassull M, Finkel Y, Colombel JF, Lémann M, Almer S.

World J Gastroenterol. 2013 Aug 14;19(30):4935-43. doi: 10.3748/wjg.v19.i30.4935.

7.

Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study.

Loulergue P, Tubach F, Salmon D, Dellamonica P, Taillan B, Thorel JB, Marteau P, Bressot C, Ravaud P, Mariette X, Lortholary O; RATIO Group.

J Infect. 2013 Dec;67(6):524-8. doi: 10.1016/j.jinf.2013.07.027. Epub 2013 Aug 3.

PMID:
23921318
8.

Serum calprotectin as a biomarker for Crohn's disease.

Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, Seidel L, Colombel JF, Louis E; GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives).

J Crohns Colitis. 2013 Dec;7(12):e678-83. doi: 10.1016/j.crohns.2013.06.008. Epub 2013 Jul 9.

PMID:
23845231
9.

Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.

Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, Couret M, Bouvard B, Debandt M, Gueit I, Gendre JP, Leone J, Nicolas N, Che D, Mariette X, Lortholary O; Research Axed on Tolerance of Biotherapies Group.

Chest. 2013 Sep;144(3):990-8. doi: 10.1378/chest.12-2820.

PMID:
23744173
10.

Genotype/phenotype analyses for 53 Crohn's disease associated genetic polymorphisms.

Jung C, Colombel JF, Lemann M, Beaugerie L, Allez M, Cosnes J, Vernier-Massouille G, Gornet JM, Gendre JP, Cezard JP, Ruemmele FM, Turck D, Merlin F, Zouali H, Libersa C, Dieudé P, Soufir N, Thomas G, Hugot JP.

PLoS One. 2012;7(12):e52223. doi: 10.1371/journal.pone.0052223. Epub 2012 Dec 27.

11.

Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease.

Allen PB, Kamm MA, Peyrin-Biroulet L, Studd C, McDowell C, Allen BC, Connell WR, De Cruz PP, Bell SJ, Elliot RP, Brown S, Desmond PV, Lemann M, Colombel JF.

Aliment Pharmacol Ther. 2013 Feb;37(4):438-44. doi: 10.1111/apt.12187. Epub 2012 Dec 22.

PMID:
23278192
12.

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH.

Nature. 2012 Nov 1;491(7422):119-24. doi: 10.1038/nature11582.

13.

Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group.

N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572.

14.

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, Lémann M; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Lancet. 2012 Dec 1;380(9857):1909-15. doi: 10.1016/S0140-6736(12)61084-8. Epub 2012 Oct 10.

PMID:
23063316
15.

Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.

D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M; International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee Clincom of the European Crohn's and Colitis Organisation (ECCO).

Gastroenterology. 2012 Dec;143(6):1461-9. doi: 10.1053/j.gastro.2012.09.031. Epub 2012 Sep 20. Review.

PMID:
23000597
16.

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.

Hébuterne X, Lémann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, D'Haens G, Mitchev K, Ernault É, Vermeire S, Brixi-Benmansour H, Moreels TG, Mary JY, Marteau P, Colombel JF.

Gut. 2013 Feb;62(2):201-8. doi: 10.1136/gutjnl-2012-302262. Epub 2012 Apr 23.

17.

Clinical predictors at diagnosis of disabling pediatric Crohn's disease.

Savoye G, Salleron J, Gower-Rousseau C, Dupas JL, Vernier-Massouille G, Fumery M, Merle V, Lerebours E, Cortot A, Turck D, Salomez JL, Lemann M, Colombel JF, Duhamel A.

Inflamm Bowel Dis. 2012 Nov;18(11):2072-8. doi: 10.1002/ibd.22898. Epub 2012 Jan 31.

PMID:
22294515
18.

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group.

Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23.

PMID:
22271569
19.

High frequency of fatal haemophagocytic lymphohistiocytosis syndrome in enteropathy-associated T cell lymphoma.

Amiot A, Allez M, Treton X, Fieschi C, Galicier L, Joly F, Gornet JM, Oksenhendler E, Lémann M, Bouhnik Y.

Dig Liver Dis. 2012 Apr;44(4):343-9. doi: 10.1016/j.dld.2011.10.008. Epub 2011 Nov 18.

PMID:
22100722
20.

Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.

Feagan BG, Lémann M, Befrits R, Connell W, D'Haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg M, Sorrentino D, van der Woude CJ, Vermeire S, Rutgeerts P.

Inflamm Bowel Dis. 2012 Jan;18(1):152-60. doi: 10.1002/ibd.21870. Epub 2011 Oct 29.

PMID:
22038857
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk